MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Liraglutide 1 endocrinologydiseasesdrugs
amyloidosis 1 endocrinologydiseases
fenofibrate 1 endocrinologydiseasesdrugs
hyperglycemia 1 endocrinologydiseases
lipodystrophy 1 endocrinologydiseases
obesity 4 endocrinologydiseases
sitagliptin 2 endocrinologydiseasesdrugs
Exenatide 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.


Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Exenatide 27902 myocardial infarction or nonfatal stroke was significantly lower for semaglutide than for placebo ([106]). Exenatide is an exendin-4-based GLP-1 receptor agonist which is a once-weekly, injectable, extended-release formulation
Exenatide 28032 exendin-4-based GLP-1 receptor agonist which is a once-weekly, injectable, extended-release formulation drug. The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) assessed the long-term cardiovascular safety and efficacy
Liraglutide 27418 improvement of the metabolic environment through control of blood glucose, insulin and Fas ([105]). The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial showed that
fenofibrate 17937 ([66]). In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, PPAR-α agonist fenofibrate treatment was associated with a statistically non-significant trend towards a reduction in the 5-year
sitagliptin 30545 cardiovascular outcomes studies EXAMINE trial ([110]) of alogliptin vs standard care and TECOS trial ([111]) of sitagliptin both showed no increase in the overall risk of hospitalization for HF among patients randomly assigned
sitagliptin 30678 increase in the overall risk of hospitalization for HF among patients randomly assigned to alogliptin and sitagliptin , vs standard care respectively. Meta-analysis of several large cohorts of patients with T2D, the use
Select Disease Character Offset Disease Term Instance
amyloidosis 5659 diastolic dysfunction ([22], [23]). In a larger study of consecutive patients referred for CMR without amyloidosis , investigators showed higher median ECV in patients with diabetes (n = 231) than in those without
hyperglycemia 31304 nonalcoholic steatohepatitis ([114]).Finally, inhibitors of sodium–glucose cotransporter 2 reduce rates of hyperglycemia in patients with T2D by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion
lipodystrophy 22908 accompanied by cardiac structural and functional changes ([82]).Ectopic and visceral adiposity or ‘acquired lipodystrophy ’ is linked to insulin resistance and diabetes ([83]). Multiple studies support the concept that insulin
obesity 4370 diabetes itself can cause left ventricular dilatation and eccentric remodelling in the absence of CAD, obesity or hypertension ([19]). Further, LV concentric remodelling was shown to be more strongly predictive
obesity 17548 consequently leading to a shift away from FA metabolism towards glucose metabolism. In animal models of obesity and impaired glucose tolerance, meldonium reduced plasma insulin concentration and increased cardiac
obesity 21173 fat may also play a role in the pathogenesis of cardiomyopathy process associated with diabetes and obesity ([75]). Computed tomography (CT), MRI, ultrasonography and 1H-MRS have all been used to quantify adipose
obesity 26247 primary mediator of beneficial metabolic effects after bariatric surgery, with its eating-inhibitory, anti obesity and antidiabetes effects ([101]). The principal determinants of the levels of active plasma GLP-1 include

You must be authorized to submit a review.